The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Of adaptive and factorial designs

A biostatistician’s interpretation of last week’s ODAC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Donald A. Berry, PhD
Professor and founding chair, Department of Biostatistics, Founding head, Division of Quantitative Sciences, MD Anderson Cancer Center; Senior statistical consultant and founder, Berry Consultants, LLC
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma

FDA has granted an accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
Byline
Donald A. Berry, PhD
Professor and founding chair, Department of Biostatistics, Founding head, Division of Quantitative Sciences, MD Anderson Cancer Center; Senior statistical consultant and founder, Berry Consultants, LLC
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account